1. Scrip
  2. >>Leadership

BioMarin’s Bienaimé To Retire With Sales And Earnings Growth On Track

 
• By Jessica Merrill

Genentech CEO Alexander Hardy will succeed Jean-Jacques Bienaimé, who has led the rare disease specialist for 18 years. Gene therapy Roctavian has gotten off to a slow commercial start.

BioMarin CEO Jean-Jacques Bienaimé • Source: BioMarin (Richard Morgenstein)

BioMarin Pharmaceutical Inc. CEO Jean-Jacques Bienaimé will retire after an 18-year run leading the rare disease specialist toward a longtime goal to achieve profitability. That goal was reached last year for the first time and BioMarin is on track to generate net income of $170m-$210m in 2023.

Key Takeaways
  • Biomarin CEO Jean-Jacques Bienamé will be succeeded by Genentech CEO Alexander Hardy effective on 1 December.
  • BioMarin said it is an ideal time for change with the company positioned on a growth trajectory

Bienaimé will be succeeded by Genentech, Inc.  CEO Alexander Hardy effective 1 December

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.